论文部分内容阅读
放射性药物体内治疗方法有可能超过目前放疗和化疗,因为它有三个特点:(1)放射性药物给予靶组织的剂量比常规放疗要大得多。(2)放射性药物治疗后白血病和其它癌肿的发病率较低。(3)这种治疗是非侵入性和非创伤性的。上述观点是由于1946年以来,Na~(181)I治疗了近一百万例甲状腺机能亢进症,约5000例分化甲状腺癌;NaH_2PO_4(~(32)P)治疗25万例真性红细胞增多症。因此,作者能作出相当有力的和自信的论述。一、选择性的靶组织照射(一) Graves病:用Na~(121)I治疗Graves′病,如果甲状腺24小时摄取为50%的话,甲状腺的平均剂
Radiopharmaceutical in vivo treatment may exceed current radiotherapy and chemotherapy because it has three characteristics: (1) The dose of radiopharmaceuticals to the target tissue is much larger than that of conventional radiotherapy. (2) The incidence of leukemia and other cancers after radiopharmaceutical treatment is low. (3) This treatment is non-invasive and non-invasive. The above view is that since 1946, Na~(181)I has treated nearly 1 million cases of hyperthyroidism, about 5000 cases of differentiated thyroid cancer, and NaH2PO4(~(32)P) has treated 250,000 cases of polycythemia vera. Therefore, the author can make a very strong and confident discussion. I. Selective Target Tissue Irradiation (I) Graves Disease: Treatment of Graves’ Disease with Na~(121)I If the thyroid gland intake is 50% at 24 hours, the thyroid average agent